Eli Lilly and Company (LLY) fundamentals: overall 63/100 — StockQuotient
LLY Healthcare
Eli Lilly and Company
$1,188.72+2.70%
Price as of close on Oct 7, 2026
Basics
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
United States
Market cap
1.06T USD
Enterprise value
1.12T USD
Full-time employees
50,000
This snapshot is over eight days old. A refresh may be pending.
Overall health
Drawback:higher risk than most peers: less short-term liquidity (current ratio 1.35 vs a peer median of 2.57) and more debt relative to equity (1.62× vs a peer median of 0.22×)higher risk: less liquidity (current ratio 1.35 vs peers 2.57) and more debt vs equity (1.62× vs peers 0.22×)
About average: valuation
Ranks #294 of 1,153 healthcare companies (top 26%)
Since last quarter: No major changeValuation also moves with the share price every day.
Why it changed since the Sep 30, 2026 close: Score 51 → 50
Peer companies moved-1
Each step re-scores the company against its peers as they were on Oct 1, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Latest filing: what changed
Quarter ended Jun 30, 2026 · filed Aug 5, 2026 · compared with the quarter ended Mar 31, 2026
No major changes
Debt up 27%
Previous quarter
Latest quarter
Change
Revenue (12 months)
72.2B USD
79.7B USD
+10.3%
Net income (12 months)
25.3B USD
26.7B USD
+5.7%
Operating margin
43.6%
42.2%
−1.4 pts
Debt
43.4B USD
54.9B USD
+26.6%
Cash
5.3B USD
8.9B USD
+69.4%
Shares outstanding
941.7M
941.4M
−0.0%
From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.
Industry valuation context
Sector: Healthcare · 301 companies
Valuations in Healthcare are within their usual range since 2016.
52% of months since 2016 were valued lower than now.
19% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values +8% and earnings +24% (medians): earnings grew faster than prices.
Median price-to-sales is +63% vs the whole market, against a usual +119%.
2016Shaded: most expensive fifth of its range2026
Shown for Healthcare: too few Drug Manufacturers - General companies have a long enough history of their own.
Earnings-based measures are left out for now because many companies in Healthcare are losing money.
Describes valuations since 2016; it does not predict prices. US companies worth $1B+, from SEC filings and month-end prices, as of Aug 2026. Today's companies and industry labels are used throughout. Measured on sales and free cash flow yields. How this works
Financials
Fiscal years from SEC annual filings · change vs the prior year
Key ratios
FY 2021
FY 2022
FY 2023
FY 2024
FY 2025
Change
Gross margin
74.2%
76.8%
79.2%
81.3%
83.0%
▲ 1.7 pts
Operating margin
22.4%
25.0%
18.9%
28.6%
40.4%
▲ 12 pts
Net margin
19.7%
21.9%
15.4%
23.5%
31.7%
▲ 8.2 pts
Return on assets (ROA)
11.4%
12.6%
8.2%
13.5%
18.4%
▲ 4.9 pts
Return on equity (ROE)
62.2%
58.6%
48.6%
74.2%
77.8%
▲ 3.6 pts
Current ratio
1.23×
1.05×
0.94×
1.15×
1.58×
▲ 37%
Quick ratio
0.97×
0.80×
0.73×
0.89×
1.19×
▲ 34%
Debt to equity
1.88×
1.53×
2.35×
2.37×
1.60×
▼ 32%
Interest coverage
18.71×
21.49×
13.29×
16.52×
29.39×
▲ 78%
LLY price history
Price history is added with the daily price update and will appear after the next one.